Janux Therapeutics, Inc. Common Stock (JANX) is a publicly traded Healthcare sector company. As of May 21, 2026, JANX trades at $14.15 with a market cap of $855.61M and a P/E ratio of -7.74. JANX moved +4.24% today. Year to date, JANX is +4.73%; over the trailing twelve months it is -43.31%. Its 52-week range spans $12.12 to $71.71. Analyst consensus is strong buy with an average price target of $39.79. Rallies surfaces JANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes JANX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $14.15 |
| Market Cap | $855.61M |
| P/E Ratio | -7.74 |
| EPS | $-1.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $71.71 |
| 52-Week Low | $12.12 |
| Volume | 931.95K |
| Avg Volume | 0 |
| Revenue (TTM) | $13.73M |
| Net Income | $-114.48M |
| Gross Margin | 0.00% |
15 analysts cover JANX: 0 strong buy, 13 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.79.